UPCC 18822: Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma
Enrolling By Invitation
99 years and younger
All
33 participants needed
1 Location
Brief description of study
Please refer to Protocol Section 3.0. Please refer to Protocol Section 3.1. Please refer to Protocol Section 3.2.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
14 Jun 2023.
Study ID: 851597
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
